Status:
WITHDRAWN
Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients
Lead Sponsor:
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Collaborating Sponsors:
Taipei Veterans General Hospital, Taiwan
Conditions:
End-Stage Renal Disease
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The study is prospectively initiated to: (1) evaluate the alterations in platelet function to aspirin therapy and the prevalence of aspirin resistance in patients with chronic kidney disease undergoin...
Eligibility Criteria
Inclusion
- patients with end-stage renal disease who are undergoing long-term hemodialysis.
Exclusion
- Patients will be excluded if there is evidence of
- a recent history of acute uremia,
- previous adverse reaction to a aspirin or history of aspirin hypersensitivity (eg, aspirin-induced asthma or angioedema),
- concurrent treatment with other antiplatelet agent (clopidogrel or ticlopidine), steroidal drugs, or nonsteroidal anti-inflammatory drugs,
- high immediate risk for bleeding (eg, active peptic ulceration, recent injury, or hemophilia), or
- life-threatening condition other than end-stage renal disease or vascular disease (eg, non-skin cancer).
Key Trial Info
Start Date :
February 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 15 2018
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01198379
Start Date
February 1 2010
End Date
January 15 2018
Last Update
January 17 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei Veterans General Hospital
Taipei, Taiwan